Bracco, Novation partner for MR contrast agents

TriMed Staff | | Health Imaging | Diagnostic Imaging
Bracco Diagnostics and Novation, a healthcare group purchasing organization, have signed an agreement making available Bracco’s MRI contrast media products to VHA, University HealthSystem Consortium and Provista members represented by Novation, through March 2010.

The agreement includes Bracco’s MultiHance (gadobenate dimeglumine) injection, 529 mg/mL, approved in the United States for central nervous system (CNS) MRI, as well as ProHance (gadoteridol) injection, 279.3 mg/mL, a macrocyclic MR contrast agent available in the United States since 1992, according to Bracco.

The agreement is effective Oct. 1 and extends through March 31, 2010, according to the Irving, Texas-based Novation.

TriMed Staff

Related Content

AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?
Speaker laments radiology’s major contribution to climate change
Radiologist accuracy takes a hit overnight, especially with advanced imaging exams

Around the web

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.